ATE205537T1 - Verwendung von plasmiden zur herstellung eines impfstoffs bei mensch und tier - Google Patents

Verwendung von plasmiden zur herstellung eines impfstoffs bei mensch und tier

Info

Publication number
ATE205537T1
ATE205537T1 AT97400796T AT97400796T ATE205537T1 AT E205537 T1 ATE205537 T1 AT E205537T1 AT 97400796 T AT97400796 T AT 97400796T AT 97400796 T AT97400796 T AT 97400796T AT E205537 T1 ATE205537 T1 AT E205537T1
Authority
AT
Austria
Prior art keywords
vivo
vaccine
virus
vector
infected
Prior art date
Application number
AT97400796T
Other languages
English (en)
Inventor
David Klatzmann
Jean-Loup Salzmann
Original Assignee
Univ Paris Curie
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Paris Curie filed Critical Univ Paris Curie
Application granted granted Critical
Publication of ATE205537T1 publication Critical patent/ATE205537T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C03—GLASS; MINERAL OR SLAG WOOL
    • C03C—CHEMICAL COMPOSITION OF GLASSES, GLAZES OR VITREOUS ENAMELS; SURFACE TREATMENT OF GLASS; SURFACE TREATMENT OF FIBRES OR FILAMENTS MADE FROM GLASS, MINERALS OR SLAGS; JOINING GLASS TO GLASS OR OTHER MATERIALS
    • C03C17/00—Surface treatment of glass, not in the form of fibres or filaments, by coating
    • C03C17/28—Surface treatment of glass, not in the form of fibres or filaments, by coating with organic material
    • C03C17/30—Surface treatment of glass, not in the form of fibres or filaments, by coating with organic material with silicon-containing compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
    • C09D—COATING COMPOSITIONS, e.g. PAINTS, VARNISHES OR LACQUERS; FILLING PASTES; CHEMICAL PAINT OR INK REMOVERS; INKS; CORRECTING FLUIDS; WOODSTAINS; PASTES OR SOLIDS FOR COLOURING OR PRINTING; USE OF MATERIALS THEREFOR
    • C09D4/00—Coating compositions, e.g. paints, varnishes or lacquers, based on organic non-macromolecular compounds having at least one polymerisable carbon-to-carbon unsaturated bond ; Coating compositions, based on monomers of macromolecular compounds of groups C09D183/00 - C09D183/16
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16622—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16023—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16051—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16061—Methods of inactivation or attenuation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Materials Engineering (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Physics & Mathematics (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Plant Pathology (AREA)
  • Geochemistry & Mineralogy (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
AT97400796T 1996-04-05 1997-04-07 Verwendung von plasmiden zur herstellung eines impfstoffs bei mensch und tier ATE205537T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9604370A FR2747046B1 (fr) 1996-04-05 1996-04-05 Nouveaux vaccins issus de plasmovirus
US09/166,147 US6140114A (en) 1996-04-05 1998-10-05 Defective viral vaccine particles obtained in vivo or ex vivo

Publications (1)

Publication Number Publication Date
ATE205537T1 true ATE205537T1 (de) 2001-09-15

Family

ID=26232637

Family Applications (1)

Application Number Title Priority Date Filing Date
AT97400796T ATE205537T1 (de) 1996-04-05 1997-04-07 Verwendung von plasmiden zur herstellung eines impfstoffs bei mensch und tier

Country Status (10)

Country Link
US (1) US6140114A (de)
EP (2) EP1138773A2 (de)
JP (1) JP2000508893A (de)
AT (1) ATE205537T1 (de)
AU (1) AU2394297A (de)
CA (1) CA2251027C (de)
DE (1) DE69706593T2 (de)
ES (1) ES2164309T3 (de)
FR (1) FR2747046B1 (de)
WO (1) WO1997038118A1 (de)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100615117B1 (ko) * 1997-09-15 2006-08-22 제네틱 이뮤너티, 엘엘씨. 피부의 항원제시 세포에 유전자를 전달하는 방법
WO1999019501A1 (en) * 1997-10-14 1999-04-22 Institute For Vaccine Development Non-integrating dna vector of retroviral origin having high-protein expression, and secreted immunogenic antigens
JP2003535565A (ja) * 1998-12-31 2003-12-02 アーチ ディベロプメント コーポレイション 新生物疾患の治療に有用な組換え単純ヘルペスウイルス
US20040105871A1 (en) * 2000-03-02 2004-06-03 Robinson Harriet L. Compositions and methods for generating an immune response
WO2002072754A2 (en) * 2001-03-08 2002-09-19 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Mva expressing modified hiv envelope, gag, and pol genes
US20020106798A1 (en) 2000-03-02 2002-08-08 Robinson Harriet L. DNA expression vectors and methods of use
US8623379B2 (en) * 2000-03-02 2014-01-07 Emory University Compositions and methods for generating an immune response
JP2004535151A (ja) * 2000-10-10 2004-11-25 インスティトゥート フューア ヴィロロギー タイルレヒツフェヒゲス インスティトゥート アン デア ヴェテリネーアメディツィニーシェン ウニヴェルズィテート ヴィーン ウイルス性成分の活性および／または特異性の評価に対する新システム
EP1201750A1 (de) * 2000-10-26 2002-05-02 Genopoietic Synthetische Viren und ihre Verwendungen
AU2002255532A1 (en) * 2001-02-13 2002-10-15 Joseph D. Mosca Biological carriers for induction of immune responses
EP2055316A1 (de) * 2003-09-09 2009-05-06 VIRxSYS Corporation Lentivirale, vektorbasierte Ansätze zur Erzeugung einer Immunantwort auf HIV bei Menschen
CN100549021C (zh) * 2004-05-27 2009-10-14 森托科尔公司 猕猴前列腺特异性抗原
AU2005329405A1 (en) * 2004-06-15 2006-09-28 Centocor, Inc. Method for screening agents against human prostate disease
WO2006036406A2 (en) * 2004-08-25 2006-04-06 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Live microbial microbicides
AU2006252406B2 (en) * 2005-06-01 2012-05-17 California Institute Of Technology Method of targeted gene delivery using viral vectors
GB0526211D0 (en) * 2005-12-22 2006-02-01 Oxford Biomedica Ltd Viral vectors
DK2520168T3 (da) * 2006-07-21 2014-04-14 California Inst Of Techn Målrettet gen-tilførsel til dendrit-cellevaccination
WO2008102368A1 (en) * 2007-02-21 2008-08-28 Rajesh Shah Medicinal formulation containing a combination of hiv type i and hiv type ii
WO2011011584A1 (en) 2009-07-24 2011-01-27 Immune Design Corp Lentiviral vectors pseudotyped with a sindbis virus envelope glycoprotein
WO2011119920A2 (en) 2010-03-25 2011-09-29 Oregon Health & Science University Cmv glycoproteins and recombinant vectors
US8323662B1 (en) 2012-03-30 2012-12-04 Immune Design Corp. Methods useful for generating highly mannosylated pseudotyped lentiviral vector particles comprising a Vpx protein
JP2015512263A (ja) 2012-03-30 2015-04-27 イミューン デザイン コーポレイション Ｄｃ−ｓｉｇｎを発現する細胞に対して改善された形質導入の有効性を有するレンチウイルスベクター粒子
US9713635B2 (en) 2012-03-30 2017-07-25 Immune Design Corp. Materials and methods for producing improved lentiviral vector particles
US11091775B2 (en) 2016-06-22 2021-08-17 Oregon Health And Science University Recombinant cytomegalovirus vectors as vaccines for tuberculosis
EP3697806A4 (de) 2017-10-17 2021-10-27 International AIDS Vaccine Initiative, Inc. Tuberkulose-antigen-kassetten

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1645635A3 (de) * 1989-08-18 2010-07-07 Oxford Biomedica (UK) Limited Replikationdefiziente Rekombinante Retroviren, die eine palliative Wirkung exprimieren
US5512421A (en) * 1991-02-19 1996-04-30 The Regents Of The University Of California Generation, concentration and efficient transfer of VSV-G pseudotyped retroviral vectors
DE69332519T2 (de) * 1992-02-28 2003-07-17 Syngenix Ltd Defekte verpackende nicht-oncoviren vektoren aus mpmv
WO1993020220A1 (en) * 1992-03-27 1993-10-14 Whitehead Institute For Biomedical Research Non-infectious hiv particles and uses therefor
EP0611822B1 (de) * 1993-02-17 2002-05-22 Wisconsin Alumni Research Foundation Retroviren vom Typ "more-complex", die LTR von gemischtem Typ enthalten und deren Anwendungen
FR2716459B1 (fr) * 1994-02-22 1996-05-10 Univ Paris Curie Système hôte-vecteur utilisable en thérapie génique.
WO1995026411A2 (en) * 1994-03-25 1995-10-05 The Uab Research Foundation Composition and methods for creating syngeneic recombinant virus-producing cells
FR2722208B1 (fr) * 1994-07-05 1996-10-04 Inst Nat Sante Rech Med Nouveau site interne d'entree des ribosomes, vecteur le contenant et utilisation therapeutique
AT402898B (de) * 1994-08-08 1997-09-25 Int Centre Genetic Eng & Bio Molekulares präsentiersystem
US6080408A (en) * 1994-08-22 2000-06-27 Connaught Laboratories Limited Human immunodeficiency virus type 1 nucleic acids devoid of long terminal repeats capable of encoding for non-infectious, immunogenic, retrovirus-like particles
CZ259197A3 (cs) * 1995-02-24 1998-01-14 Clipmate Corporation Rozbušková sestava, balení rozbuškových sestav a způsob sestavování rozbušky a zesilovací nálože

Also Published As

Publication number Publication date
EP0799893B1 (de) 2001-09-12
ES2164309T3 (es) 2002-02-16
WO1997038118A1 (fr) 1997-10-16
US6140114A (en) 2000-10-31
JP2000508893A (ja) 2000-07-18
FR2747046A1 (fr) 1997-10-10
EP1138773A2 (de) 2001-10-04
CA2251027A1 (fr) 1997-10-16
DE69706593D1 (de) 2001-10-18
AU2394297A (en) 1997-10-29
CA2251027C (fr) 2009-11-10
EP0799893A1 (de) 1997-10-08
FR2747046B1 (fr) 1998-06-19
DE69706593T2 (de) 2002-07-11

Similar Documents

Publication Publication Date Title
ATE205537T1 (de) Verwendung von plasmiden zur herstellung eines impfstoffs bei mensch und tier
AU704919B2 (en) Composition for the production of therapeutic products in vivo
DK0742834T4 (da) Fremgangsmåde til fremstilling af en virusvektor på mindst 20 kb ved intermolekylær homolog rekombination i en prokaryot celle
CA2596274A1 (en) Recombinant mva virus, and the use thereof
EP1683858A3 (de) Virale Zubereitungen, Vektoren, Immunogene und Impfstoffe
ATE419368T1 (de) System zum transfer und zur expression von heterologen genen ins knochenmark in vivo
NL300313I1 (nl) Vaccin tegen humaan papillomavirus
AU1138388A (en) Hybrid rna virus
EP1923467A3 (de) Adenovirusvektoren für die Gentherapie
NZ503830A (en) Papilloma virus capsomere vaccine formulations and methods of use
RU2003118436A (ru) Модифицированный вариант вируса коровьей оспы ankara
KR970707281A (ko) 풀리뉴클레오티드 결핵 백신(A polynucleotide tuberculosis vaccine)
JPS6349077A (ja) ベクターウイルスおよびベクターウイルスを含む薬用組成物
EP0342860A3 (de) Neues Protein, Sequenze mit enthaltendem Gene, Vektoren, Verfahren zur Herstellung und Verwendung
ATE101200T1 (de) Impfstoffe gegen menschliche respiratorische viren.
AU784884B2 (en) Methods for introducing genes into mammalian subjects
EP2145961A3 (de) Adenovirus-Typ-3-Genom des Schweins
CN109135737A (zh) 一种氮掺杂碳量子点及其制备方法和应用
ATE230276T1 (de) Verfahren zur erzeugung der toleranz eines säugetierpatientes gegen verabreichung von bei gentherapie gebrauchten viralen vektoren
Chamarthy et al. A cationic peptide consists of ornithine and histidine repeats augments gene transfer in dendritic cells
CA2254082A1 (en) Metastatic colorectal cancer vaccine
ATE237629T1 (de) Rekombinanter virus der marek-krankheit, verfahren zur herstellung dieses viruses und diesen enthaltender impfstoff
CN109837245A (zh) 一种tcr敲除的靶向ny-eso-1的t细胞受体基因修饰t细胞及其制备方法和应用
AP2005A (en) Process for the selection of HIV-1 subtype C isolates, selected HIV-1 subtype C isolates, their genes and modifications and derivatives thereof.
DK257887A (da) Fremgangsmaade til fremstilling af hbcag i gaer og plasmid til brug ved udoevelse af fremgangsmaaden

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee